Neuralink’s private valuation has climbed sharply on secondary markets to estimates between $29 billion and $45 billion as of early October 2026, up from roughly $9–10 billion post-money after its June 2025 Series E round. Recent clinical milestones, including reduced daily calibration times via 50,000 hours of unlabeled patient data, new cursor-control records above 11 bits per second, and FDA breakthrough-device status for the Blindsight vision-restoration implant, have supported stronger secondary demand and additional late-stage funding rounds. With multiple patients now implanted—including the first Canadian ALS participant—and no IPO on the horizon, trader sentiment for hitting higher valuation thresholds by year-end hinges on further trial expansion, regulatory clarity, and sustained private-market appetite for neurotechnology assets amid broader biotech funding trends.